Literature DB >> 2552912

Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.

D M Coen1, D J Goldstein, S K Weller.   

Abstract

Two mutants defective in herpes simplex virus-encoded ribonucleotide reductase activity exhibited the novel phenotype of hypersensitivity to acyclovir, aphidicolin, and to a lesser extent, phosphonoacetic acid. These results have implications for acyclovir resistance and the development of drugs that potentiate acyclovir action by inhibition of viral ribonucleotide reductase.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2552912      PMCID： PMC172665          DOI： 10.1128/AAC.33.8.1395

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  37 in total

1.  Vaccinia virus-encoded ribonucleotide reductase: sequence conservation of the gene for the small subunit and its amplification in hydroxyurea-resistant mutants.

Authors:  M Slabaugh; N Roseman; R Davis; C Mathews
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.

Authors:  J M Cameron; I McDougall; H S Marsden; V G Preston; D M Ryan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

3.  Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.

Authors:  W McClements; G Yamanaka; V Garsky; H Perry; S Bacchetti; R Colonno; R B Stein
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

4.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

5.  Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2.

Authors:  E A Cohen; P Gaudreau; P Brazeau; Y Langelier
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

6.  Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.

Authors:  B M Dutia; M C Frame; J H Subak-Sharpe; W N Clark; H S Marsden
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

7.  2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.

Authors:  T Spector; J A Harrington; R W Morrison; C U Lambe; D J Nelson; D R Averett; K Biron; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

8.  Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.

Authors:  A Karlsson; J Harmenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

10.  The herpes simplex virus type 1 temperature-sensitive mutant ts1222 has a single base pair deletion in the small subunit of ribonucleotide reductase.

Authors:  V G Preston; A J Darling; I M McDougall
Journal:  Virology       Date:  1988-12       Impact factor: 3.616
View more
  15 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 3.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.

Authors:  Alicia M Waters; James M Johnston; Alyssa T Reddy; John Fiveash; Avi Madan-Swain; Kara Kachurak; Asim K Bag; G Yancey Gillespie; James M Markert; Gregory K Friedman
Journal:  Hum Gene Ther Clin Dev       Date:  2017-03       Impact factor: 5.032

5.  Transcriptional targeting of herpes simplex virus for cell-specific replication.

Authors:  S Miyatake; A Iyer; R L Martuza; S D Rabkin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain.

Authors:  L L Muldoon; G Nilaver; R A Kroll; M A Pagel; X O Breakefield; E A Chiocca; B L Davidson; R Weissleder; E A Neuwelt
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

7.  Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.

Authors:  A M Bonneau; P Kibler; P White; C Bousquet; N Dansereau; M G Cordingley
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.

Authors:  T C Heineman; J I Cohen
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

Review 9.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.